1. Technological advances in genome sequencing have led to the identification of novel driver genes mutated in renal cancer, such as PBRM1 and BAP1.
2. PBRM1 and BAP1 are two-hit tumor suppressor genes that are mutated in more than 10% of ccRCC cases.
3. PBRM1 and BAP1 mutations tend to anticorrelate with each other, and tumors with these mutations exhibit different biology and are associated with markedly different outcomes.
The article is generally reliable and trustworthy, providing a comprehensive overview of the current understanding of the roles of PBRM1 and BAP1 as novel targets for renal cell carcinoma. The article is well-referenced, citing relevant studies to support its claims, including those from reputable journals such as J Clin Oncol, Cancer Genet, Proc Natl Acad Sci U S A, Eur Urol, and Expert Rev Mol Diagn. The author also provides an update on the function of the gene products and speculates on how mutations in these genes may be exploited therapeutically.
The article does not appear to be biased or one-sided; it presents both sides equally by discussing both the potential benefits of targeting these genes as well as possible risks associated with doing so. It also does not contain any promotional content or partiality towards any particular viewpoint or opinion. Furthermore, all claims made in the article are supported by evidence from relevant studies cited throughout the text.
The only potential issue with this article is that it does not explore any counterarguments or alternative points of view regarding its claims about PBRM1 and BAP1 being novel targets for renal cell carcinoma. However, given that this is an overview article rather than a research paper exploring a specific hypothesis or argument, this lack of exploration is understandable.